Cargando…
Senolytics dasatinib and quercetin in idiopathic pulmonary fibrosis: results of a phase I, single-blind, single-center, randomized, placebo-controlled pilot trial on feasibility and tolerability
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is an age-related, chronic, irreversible fibrotic lung disease. IPF is associated with increased senescent cells burden, which may be alleviated with administration of senescent cell targeting drugs termed ‘senolytics’. We previously conducted an open-...
Autores principales: | Nambiar, Anoop, Kellogg, Dean, Justice, Jaime, Goros, Martin, Gelfond, Jonathan, Pascual, Rodolfo, Hashmi, Shahrukh, Masternak, Michal, Prata, Larissa, LeBrasseur, Nathan, Limper, Andrew, Kritchevsky, Stephen, Musi, Nicolas, Tchkonia, Tamara, Kirkland, James |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10006434/ https://www.ncbi.nlm.nih.gov/pubmed/36857968 http://dx.doi.org/10.1016/j.ebiom.2023.104481 |
Ejemplares similares
-
Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study
por: Justice, Jamie N., et al.
Publicado: (2019) -
CELLULAR SENESCENCE AS A THERAPEUTIC TARGET FOR GEROSCIENCE-GUIDED CLINICAL TRIALS
por: Justice, Jamie N, et al.
Publicado: (2019) -
Senolytics decrease senescent cells in humans: Preliminary report from a clinical trial of Dasatinib plus Quercetin in individuals with diabetic kidney disease
por: Hickson, LaTonya J., et al.
Publicado: (2019) -
Dasatinib plus quercetin prevents uterine age-related dysfunction and fibrosis in mice
por: Cavalcante, Marcelo B., et al.
Publicado: (2020) -
Orally-active, clinically-translatable senolytics restore α-Klotho in mice and humans
por: Zhu, Yi, et al.
Publicado: (2022)